Functional Brands Seeks Reverse Stock Split to Avoid Delisting, Warns of 'Total Loss of Investment'
summarizeSummary
Functional Brands Inc. is seeking shareholder approval for a reverse stock split to avoid Nasdaq delisting, explicitly warning of a "total loss of investment" if delisting occurs, and proposing a new equity incentive plan that could lead to significant dilution.
check_boxKey Events
-
Shareholder Vote on Reverse Stock Split
The Board is seeking shareholder approval for a reverse stock split, with a ratio ranging from 1-for-2 to 1-for-250, to increase the per-share price and regain compliance with Nasdaq's minimum bid price requirement by the June 29, 2026 deadline.
-
Explicit Warning of Total Loss of Investment
The company explicitly states that delisting from Nasdaq could lead to an in-court or out-of-court restructuring of liabilities, where holders of common stock and other securities 'will likely suffer a total loss of their investment'.
-
New Equity Incentive Plan Proposed
Shareholders will vote on a new 2026 Equity Incentive Plan, authorizing 4,000,000 shares of common stock for awards, along with an evergreen provision for annual increases, representing significant potential dilution for existing shareholders.
-
Delisting Risk Reiterated
The filing reiterates the Nasdaq delisting notice received on December 30, 2025, for failing to meet the $1.00 minimum bid price, and outlines the severe consequences of trading on the OTC market, including reduced liquidity and challenges in raising capital.
auto_awesomeAnalysis
Functional Brands Inc. is taking urgent measures to address its Nasdaq listing compliance and severe financial challenges. The proposed reverse stock split, with a wide potential ratio of up to 1-for-250, is a critical attempt to meet the minimum bid price requirement and avoid delisting. The company explicitly warns shareholders that delisting could lead to an in-court or out-of-court restructuring, where they "will likely suffer a total loss of their investment." This dire warning, coupled with the proposal for a new equity incentive plan authorizing significant potential dilution (4 million shares plus an evergreen provision for a nano-cap company), underscores the extreme precariousness of the company's situation. This filing provides the actionable steps in response to the going concern warning and delisting risk previously disclosed in its recent 10-K.
At the time of this filing, MEHA was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.13 to $8.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.